{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:25:49Z","timestamp":1793298349333,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ihj.2018.07.009","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T02:56:45Z","timestamp":1533869805000},"page":"S120-S125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"S3","title":["Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects"],"prefix":"10.1016","volume":"70","author":[{"given":"Nuthalapati","family":"Ramakumari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobbala","family":"Indumathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva Krishna","family":"Katkam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay Kumar","family":"Kutala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ihj.2018.07.009_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.18.S1.1","article-title":"AACE task force for management of dyslipidemia and prevention of atherosclerosis. American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis","volume":"18","author":"Jellinger","year":"2012","journal-title":"Endocr Pract"},{"issue":"8A","key":"10.1016\/j.ihj.2018.07.009_bib2","doi-asserted-by":"crossref","first-page":"95C","DOI":"10.1016\/j.amjcard.2005.12.016","article-title":"Benefit versus risk in statin treatment","volume":"97","author":"Guyton","year":"2006","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.ihj.2018.07.009_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"10.1016\/j.ihj.2018.07.009_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2009.11.033","article-title":"The genetics of statin-induced myopathy","volume":"210","author":"Ghatak","year":"2010","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.ihj.2018.07.009_bib5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/14622416.6.8.865","article-title":"Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis","volume":"6","author":"Rua\u00f1o","year":"2005","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ihj.2018.07.009_bib6","first-page":"97","article-title":"Pharmacogenomics of statins: understanding susceptibility to adverse effects","volume":"9","author":"Kitzmiller","year":"2016","journal-title":"Pharmgenomics Pers Med"},{"issue":"2","key":"10.1016\/j.ihj.2018.07.009_bib7","article-title":"Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokinetic genetic variants","volume":"5","author":"Talameh","year":"2014","journal-title":"J\u00a0Pharmacogenomics Pharmacoproteomics"},{"issue":"1","key":"10.1016\/j.ihj.2018.07.009_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18010104","article-title":"Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins","volume":"18","author":"Arrigoni","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ihj.2018.07.009_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11095-006-9159-2","article-title":"Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans","volume":"24","author":"Kivist\u00f6","year":"2007","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.ihj.2018.07.009_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) trial","volume":"5","author":"Chasman","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"issue":"5","key":"10.1016\/j.ihj.2018.07.009_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1517\/17425251003713519","article-title":"Efflux and uptake transporters as determinants of statin response","volume":"6","author":"Rodrigues","year":"2010","journal-title":"Expet Opin Drug Metabol Toxicol"},{"issue":"8A","key":"10.1016\/j.ihj.2018.07.009_bib12","doi-asserted-by":"crossref","first-page":"69C","DOI":"10.1016\/j.amjcard.2005.12.013","article-title":"National lipid association statin safety task force muscle safety expert panel. An assessment of statin safety by muscle experts","volume":"97","author":"Thompson","year":"2006","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.ihj.2018.07.009_bib13","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2217\/pgs.10.81","article-title":"Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction","volume":"11","author":"Peters","year":"2010","journal-title":"Pharmacogenomics"},{"issue":"8","key":"10.1016\/j.ihj.2018.07.009_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"37","key":"10.1016\/j.ihj.2018.07.009_bib15","doi-asserted-by":"crossref","first-page":"e1268","DOI":"10.1097\/MD.0000000000001268","article-title":"Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case-control studies","volume":"94","author":"Hou","year":"2015","journal-title":"Medicine (Baltim)"},{"issue":"9","key":"10.1016\/j.ihj.2018.07.009_bib16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"2","key":"10.1016\/j.ihj.2018.07.009_bib17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1086\/500092","article-title":"A\u00a0mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency","volume":"78","author":"Quinzii","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.ihj.2018.07.009_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1715163518768534","article-title":"Prevention and management of statin adverse effects: a practical approach for pharmacists","volume":"151","author":"Barry","year":"2018","journal-title":"Can Pharm J (Ott)"},{"issue":"3 Suppl","key":"10.1016\/j.ihj.2018.07.009_bib19","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"The national lipid association's muscle safety expert panel. An assessment by the statin muscle safety task force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"issue":"5","key":"10.1016\/j.ihj.2018.07.009_bib20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ihj.2015.12.016","article-title":"Statin therapy\/lipid lowering therapy among Indian adults with first acute coronary event: the dyslipidemia residual and mixed abnormalities in spite of statin therapy (REMAINS) study","volume":"68","author":"Jaywant","year":"2016","journal-title":"Indian Heart J"},{"issue":"1","key":"10.1016\/j.ihj.2018.07.009_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ihj.2016.07.007","article-title":"Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients","volume":"69","author":"Grover","year":"2017","journal-title":"Indian Heart J"},{"issue":"12","key":"10.1016\/j.ihj.2018.07.009_bib22","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ihj.2018.07.009_bib23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ihj.2018.07.009_bib24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1532-5415.2007.01071.x","article-title":"Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults","volume":"55","author":"Agostini","year":"2007","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.ihj.2018.07.009_bib25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00002018-200022060-00003","article-title":"HMG-CoA reductase inhibitors and myotoxicity","volume":"22","author":"Ucar","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.ihj.2018.07.009_bib26","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ihj.2018.07.009_bib27","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.clinthera.2007.08.022","article-title":"Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients","volume":"29","author":"Nichols","year":"2007","journal-title":"Clin Therapeut"},{"issue":"5","key":"10.1016\/j.ihj.2018.07.009_bib28","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1017\/cjn.2014.22","article-title":"Statin-associated autoimmune myopathies: a pathophysiologic spectrum","volume":"41","author":"Wu","year":"2014","journal-title":"Can J Neurol Sci"},{"issue":"9","key":"10.1016\/j.ihj.2018.07.009_bib29","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/phar.1981","article-title":"Impact of pharmacogenetics on efficacy and safety of statin therapy for dyslipidemia","volume":"37","author":"Maxwell","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.ihj.2018.07.009_bib30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","article-title":"Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy","volume":"79","author":"Hermann","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ihj.2018.07.009_bib31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","article-title":"Statin-induced myopathy is associated with mitochondrial complex III inhibition","volume":"22","author":"Schirris","year":"2015","journal-title":"Cell Metabol"},{"issue":"1","key":"10.1016\/j.ihj.2018.07.009_bib32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/clpt.2012.57","article-title":"The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy","volume":"92","author":"Wilke","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ihj.2018.07.009_bib33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update","volume":"96","author":"Ramsey","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"10.1016\/j.ihj.2018.07.009_bib34","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ihj.2018.07.009_bib35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2010.02.026","article-title":"Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study","volume":"211","author":"Puccetti","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ihj.2018.07.009_bib36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","article-title":"SLCO1B1 genetic variant associated with statin-induced myopathy: a proof of- concept study using the clinical practice research data link","volume":"94","author":"Carr","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ihj.2018.07.009_bib37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/tpj.2010.92","article-title":"Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin","volume":"12","author":"Brunham","year":"2012","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"10.1016\/j.ihj.2018.07.009_bib38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","article-title":"The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment","volume":"78","author":"Fiegenbaum","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ihj.2018.07.009_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01213011-200506000-00007","article-title":"Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage","volume":"15","author":"Wilke","year":"2005","journal-title":"Pharmacogenetics Genom"},{"issue":"8","key":"10.1016\/j.ihj.2018.07.009_bib40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/01.fpc.0000114762.78957.a5","article-title":"Lipid-lowering response to statins is affected by CYP3A5 polymorphism","volume":"14","author":"Kivist\u00f6","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ihj.2018.07.009_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","author":"Oh","year":"2007","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10.1016\/j.ihj.2018.07.009_bib42","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2011.07.007","article-title":"Mechanisms of statin-induced myalgia assessed by physiognomic associations","volume":"218","author":"Rua\u00f1o","year":"2011","journal-title":"Atherosclerosis"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483218302827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483218302827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T01:29:38Z","timestamp":1547256578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483218302827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":42,"alternative-id":["S0019483218302827"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2018.07.009","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2018.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Cardiological Society of India. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}